Study suggests osteoporosis rates in women are falling
Women more severely affected by Alzheimer’s than men
English girls’ wellbeing plummets as they reach teenage years, report finds
New perinatal services to be set up across Wales
Women less likely to receive basic life support for cardiac arrest from public
Lupus may contribute to pregnancy complications
NICE issues guidance for olaparib in ovarian cancer
NICE has today issued Technology Appraisal Guidance (TAG) for olaparib (Lynparza) for the treatment of platinum-sensitive relapsed (PSR) BRCA-mutated (BRCAm) high-grade serous ovarian cancer in women who have had 3 or more courses of platinum-based chemotherapy. In it’s appraisal NICE decalred that olaparib was a cost-effective option.